Skip to content
Peptide.Guide
ExperimentalMitochondrialOralDailyCarcinogenicity signal in rodentsPartial data

Cardarine

GW501516

PPARδ agonist that increases fatty-acid oxidation and endurance in preclinical models. Development halted over carcinogenicity findings in rats.

Read dosing protocol

◆ Editorial note

Non-peptide PPARδ agonist. Included for its metabolic effects that overlap with this category.

§ 01   Overview

Overview

PPARδ agonist that increases fatty-acid oxidation and endurance in preclinical models. Development halted over carcinogenicity findings in rats.

Development discontinued by GSK due to cancer signals in long-term rat studies. WADA-banned at all times.

§ 02   Mechanism

Mechanism of action

Cardarine activates PPARδ, a nuclear receptor that upregulates genes involved in fatty-acid oxidation, mitochondrial biogenesis, and endurance. It does not bind to any peptide receptor.

  • 01Improved endurance in preclinical models
  • 02Increased fatty-acid oxidation
  • 03Lipid profile improvements in early human studies

§ 03   Dosing

Dosing protocol

Standard Protocol

Dose Range
10 – 20 mg daily (research)
Route
Oral
Frequency
Daily
Cycle
Short cycles 4–8 weeks at most

§ 04   Evidence

Evidence & research

Experimental

Development discontinued by GSK due to cancer signals in long-term rat studies. WADA-banned at all times.

FDA Status

Not FDA-approved. WADA prohibited.

§ 06   News

In the news

8 articles from the last 12 months · updates hourly

§ 07   Sourcing

Sourcing & supply

Regulatory status

Research-only, no commercial channel

No commercial channel exists. Available only as a research reagent from RUO suppliers. Use in humans is not established.

No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.

Browse full supplier directory

§ 09   Safety

Safety & side effects

Side effects

  • 01Long-term carcinogenicity concern
  • 02Unknown human safety profile

Contraindications

  • 01Personal or family cancer history
  • 02Pregnancy
◆   In this categoryMore from Mitochondrial
01

MOTS-c

Mitochondrial-derived peptide that acts as an exercise mimetic, improving insulin sensitivity and metabolic flexibility.

Preclinical
02

SS-31 (Elamipretide)

Tetrapeptide that targets the inner mitochondrial membrane, stabilizes cardiolipin, and improves ATP production in dysfunctional mitochondria.

Clinical
03

5-Amino-1MQ

Small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) that increases intracellular NAD+ and SAM and may reduce adiposity.

Preclinical
04

NAD+

Central redox and signaling coenzyme; exogenous NAD+ or its precursors are used to support energy, repair, and longevity pathways.

Preclinical
05

Humanin

Mitochondrial-derived peptide with cytoprotective effects across neurons, cardiomyocytes, and beta cells; a candidate longevity signaling peptide.

Preclinical

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.